治疗差异与临床病理特征对EBV阳性弥漫大B细胞淋巴瘤生存的影响
该研究回顾性分析80例连续诊断的EBV阳性弥漫大B细胞淋巴瘤(NOS)患者,中位年龄70岁,经集中病理复核,60/80例CD30阳性。多数接受R-CHOP类方案,单因素及多因素分析显示R-CHOP类治疗和CD30阴性均与更好生存相关;倾向评分匹配分析中EBV状态对生存无显著影响。
要点
- R-CHOP类免疫化疗与EBV+ DLBCL(NOS)患者更好总生存和无进展生存相关。
- CD30阴性患者总生存和无进展生存均优于CD30阳性患者。
- 部分EBV+ DLBCL(NOS)患者合并或继发外周T细胞淋巴瘤,需警惕。
核心结论
- R-CHOP类免疫化疗在EBV+ DLBCL(NOS)中显示更优疗效,CD30表达与不良生存相关。
- 倾向评分匹配后EBV状态对无进展生存和总生存无显著影响,但数值上倾向EBV阴性更优。
研究设计与样本
- 回顾性分析连续诊断的EBV+ DLBCL(NOS)患者80例,中位年龄70岁(范围19-90岁),进行集中系统性血液病理复核。
主要发现
- 免疫组化显示60/80例患者CD30阳性。
- 9例患者在诊断或复发时合并或复合外周T细胞淋巴瘤,其中4/5例在初始DLBCL活检中检出克隆性T细胞群。
- 80%患者接受R-CHOP类方案,16例未治疗或接受强度较低方案。
- 单因素分析显示R-CHOP类治疗与总生存改善相关(P<0.0001),无进展生存边缘显著(P=0.0617);CD30阴性亦与总生存(P=0.0002)和无进展生存(P=0.0002)改善相关,多因素分析中保持显著。
- 倾向评分匹配分析中EBV状态对总生存(P=0.116)和无进展生存(P=0.269)无显著影响。
临床怎么用
- EBV+ DLBCL(NOS)患者应优先考虑R-CHOP类免疫化疗。
- CD30表达状态可作为预后参考,并提示探索CD30靶向等基于肿瘤生物学的替代治疗。
- 诊断或复发时需警惕合并外周T细胞淋巴瘤的可能。
局限性
- 回顾性设计,样本量有限(n=80),治疗异质性大,部分患者未接受标准方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with EBV-positive diffuse large B cell lymphoma not otherwise specified (EBV+ DLBCL (NOS)) recurrently present with advanced age and reduced performance status. They are therefore insufficiently represented in clinical trials and treatment is likely to differ. Here we assess clinicopathological characteristics, therapeutic variability and clinical outcome in the largest consecutively diagnosed EBV+ DLBCL (NOS) cohort published to date (n = 80; median age 70 years; range 19-90). Centralized and systematic haematopathological panel review was performed. By immunohistochemistry 60/80 patients were CD30-positive. Further, we identified nine EBV+ DLBCL (NOS) patients with associated or composite peripheral T cell lymphoma at diagnosis or relapse (preceded by clonal T cell populations within the initial DLBCL biopsy in 4/5 cases). Most patients (80%) were treated with R-CHOP-type therapy and 16 patients received none or less intensiveprotocols. Upon univariate analysis both R-CHOP-type therapy (OS: P < 0.0001; PFS: P = 0.0617) and negativity for CD30 (OS: P = 0.0002; PFS: P = 0.0002) showed a protective 66 effect, maintained upon multivariate analysis. In a propensity-score matched analysis with a cohort of non-EBV+ DLBCL (NOS) patients, balanced for all revised-international prognostic index factors, we found an EBV-association to hold no significant impact on progression-free and overall survival whilst exhibiting a trend favouring EBV-negativity (OS: P = 0.116; PFS: P = 0.269). Our findings provide insight into the clinical course of EBV+ DLBCL (NOS), highlight the ramifications of CD30-expression and underline the superior therapeutic efficacy of R-CHOP immunochemotherapy. Alternative therapies, incorporating tumour biology (e.g. CD30 directed therapies) need to be explored in EBV+ DLBCL (NOS) patients. Moreover our data advert to the close relationship between EBV+ DLBCL (NOS) and peripheral T cell lymphomas.
引用
- Witte HM, Merz H, Biersack H, et al. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma. Br J Haematol. 2020. PMID: 31958882. doi:10.1111/bjh.16342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。